Literature DB >> 26320066

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.

Steven A Feldman1, Yasmine Assadipour2, Isaac Kriley2, Stephanie L Goff2, Steven A Rosenberg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26320066      PMCID： PMC6295669          DOI： 10.1053/j.seminoncol.2015.05.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  35 in total

1.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

2.  Socializing Individualized T-Cell Cancer Immunotherapy.

Authors:  Richard G Vile
Journal:  Mol Ther       Date:  2016-08       Impact factor: 11.454

Review 3.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 4.  Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era.

Authors:  Gerald P Linette; Beatriz M Carreno
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

5.  Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Authors:  Shilpak Chatterjee; Paramita Chakraborty; Anusara Daenthanasanmak; Supinya Iamsawat; Gabriela Andrejeva; Libia A Luevano; Melissa Wolf; Uday Baliga; Carsten Krieg; Craig C Beeson; Meenal Mehrotra; Elizabeth G Hill; Jeffery C Rathmell; Xue-Zhong Yu; Andrew S Kraft; Shikhar Mehrotra
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

Review 6.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 7.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

8.  Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion.

Authors:  Mohsen Ibrahim; Davide Scozzi; Kelsey A Toth; Donatella Ponti; Daniel Kreisel; Cecilia Menna; Elena De Falco; Antonio D'Andrilli; Erino A Rendina; Antonella Calogero; Alexander S Krupnick; Andrew E Gelman
Journal:  J Immunol       Date:  2017-12-06       Impact factor: 5.422

9.  Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Authors:  Anirban Banerjee; Krishnamurthy Thyagarajan; Shilpak Chatterjee; Paramita Chakraborty; Pravin Kesarwani; Myroslawa Soloshchenko; Mazen Al-Hommrani; Kristina Andrijauskaite; Kelly Moxley; Harinarayanan Janakiraman; Matthew J Scheffel; Kristi Helke; Kent Armenson; Viswanathan Palanisamy; Mark P Rubinstein; Elizabeth-Garrett Mayer; David J Cole; Chrystal M Paulos; Michael I Nishimura; Shikhar Mehrotra
Journal:  Cancer Res       Date:  2016-07-27       Impact factor: 12.701

Review 10.  Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Authors:  V Finisguerra; H Prenen; M Mazzone
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.